drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Targeted haploidentical neoantigen T-cell therapy: ex vivo–expanded donor-derived T cells (≥50% HLA match; HLA-A*02/11/24 alleles) primed to patient-specific tumor neoantigens to recognize and kill EBV-positive malignant T cells via TCR-mediated recognition and cytotoxic effector mechanisms.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
TCR SELECTED T CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Donor-derived haploidentical T cells are ex vivo expanded and primed/selected for reactivity to patient-specific tumor neoantigens. After infusion, they use native TCRs to recognize neoantigen peptides presented by HLA-A*02/11/24 on EBV-positive malignant T cells and eliminate them via perforin/granzyme-mediated cytotoxicity.
drug_name
hNeo-T
nct_id_drug_ref
NCT06224049